CAJ | 학술논문

目的观察辛伐他汀对代谢综合征(MS)并存良性前列腺增生症(BPH)患者的下尿路症状(LUTS)影响.方法 2011年2-6月我科门诊和住院患者中MS并存BPH继发LUTS患者共30例,检查并记录国际前列腺症状评分(IPSS)、生活质量评分(QOL)、最大尿流率(MFR)、前列腺体积、肝肾功能、尿常规后,随机分为两组:联合用药组给予辛伐他汀40 mg和坦索罗辛0.2 mg口服,每晚1次；单药组给予坦索罗辛0.2 mg口服,每晚1次,治疗8周后复诊,复查上述指标,对治疗的有效性和安全性进行评价.结果联合用药组和单药组IPSS、QOL、和MFR与治疗前比较,差异均有统计学意义,前列腺体积差异无统计学意义.联合用药组治疗后IPSS评分变化值为(6.4±4.4)分,单药组为(4.2±3.3)分,两组比较差异有统计学意义(P＜0.05),联合用药组症状改善优于单药组.两组均无不良事件发生.结论辛伐他汀对MS并存BPH患者的LUTS有改善作用,联合用药组耐受性良好,未出现明显不良事件.
목적 관찰신벌타정대대사종합정(MS)병존량성전렬선증생증(BPH)환자적하뇨로증상(LUTS)영향.방법 2011년2-6월아과문진화주원환자중MS병존BPH계발LUTS환자공30례,검사병기록국제전렬선증상평분(IPSS)、생활질량평분(QOL)、최대뇨류솔(MFR)、전렬선체적、간신공능、뇨상규후,수궤분위량조:연합용약조급여신벌타정40 mg화탄색라신0.2 mg구복,매만1차；단약조급여탄색라신0.2 mg구복,매만1차,치료8주후복진,복사상술지표,대치료적유효성화안전성진행평개.결과 연합용약조화단약조IPSS、QOL、화MFR여치료전비교,차이균유통계학의의,전렬선체적차이무통계학의의.연합용약조치료후IPSS평분변화치위(6.4±4.4)분,단약조위(4.2±3.3)분,량조비교차이유통계학의의(P＜0.05),연합용약조증상개선우우단약조.량조균무불량사건발생.결론 신벌타정대MS병존BPH환자적LUTS유개선작용,연합용약조내수성량호,미출현명현불량사건.
Objective To determine whether simvastatin alleviates lower urinary tract symptoms (LUTS) in patients with metabolic syndrome (MS) coexisting with benign prostate hyperplasia (BPH) and explore an optimized scheme of treatment. Methods From February to June in 2011,30 male subjects with MS and LUTS caused by BPH in out-patients and in-patients from geriatric department were recruited.The patients were randomly assigned to receive orally simvastatin (40 mg) and tamsulosin (0.2 mg) quaque noete as combination treatment group or only tamsulosin (0.2 mg,quaque nocte) as single treatment group for 8 weeks.International prostate symptoms score (IPSS),quality of life (QOL),maximum flow rate (MFR) and prostate volume (PV),liver enzymes,creatinine and routine urine test were monitored to evaluate the effectiveness and safety before and after the treatment.Results In the two groups,the significant differences were found in the levels of IPSS,QOL and MFR,while there was no difference in PV between pre-treatment and post-treatment.The scores of IPSS after treatment were (6.4 ± 4.4) in combination treatment group and(4.2±3.3)in single treatment group (P＜0.05),and there were significant difference in scores of IPSS before and after the treatment between two groups (P＜0.05),suggesting better improvement in combination treatment group than in single treatment group.In two groups,there were no adverse events,and no changes were found in liver and kidney function,muscle enzymes and routine urine test.Conclusions Combined tamsulosin and simvastatin treatment may alleviate LUTS caused by BPH and are well tolerated with no adverse events.